Valitor has been awarded a Phase I SBIR grant from the National Eye Institute. This project is designed to apply our technology towards localized and sustained treatments in ophthalmology. Specifically, we will validate a long-acting anti-VEGF drug to treat diabetic macular edema.
Valitor is proud to announce the final close of our Series A financing, co-lead by the Berkeley Catalyst Fund and ShangPharma Innovations. This round oversubscribed our initial offering, and we raised
Valitor has been awarded a Phase I SBIR grant from the National Cancer Institute. This project will support validation of our platform technology to generate long-acting immunotherapies that can provi
Valitor has been awarded a Phase I SBIR grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases. This project will continue the development of a long-acting anti-inflammat